{
    "clinical_study": {
        "@rank": "139723", 
        "arm_group": [
            {
                "arm_group_label": "BI 639667 dose 1", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 2", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 3", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 4", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 5", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 5", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 6", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 6", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }, 
            {
                "arm_group_label": "BI 639667 dose 7", 
                "arm_group_type": "Experimental", 
                "description": "single dose given as oral solution"
            }, 
            {
                "arm_group_label": "Placebo dose 7", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo solution"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to investigate the safety and tolerability of BI\n      639667 in healthy male subjects following oral administration of single rising doses up to\n      700 mg.\n\n      Secondary objectives are the exploration of the pharmacokinetics (PK) including dose\n      proportionality as well as investigation of linearity and pharmacodynamics (PD) of BI 639667\n      after single dosing and the assessment of the PK/PD relationship."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male subjects\n\n          2. age of 18 to 50 years\n\n          3. body mass index (BMI) of 18.5 to 29.9 kg/m2\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including BP, PR or ECG) is deviating from\n             normal and judged as clinically relevant by the investigator\n\n          2. Repeated measurement of systolic blood pressure greater than 140 mmHg, diastolic\n             blood pressure greater than 90 mmHg, or pulse rate outside the range of 50 to 90 mmHg\n             at screening\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any evidence of a concomitant disease judged as clinically relevant by the\n             investigator\n\n          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial\n             medication (except appendectomy and simple hernia repair)\n\n          7. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133482", 
            "org_study_id": "1352.1", 
            "secondary_id": "2014-001061-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 639667 dose 1", 
                "description": "oral solution BI 639667, dose 1", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 3", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 2", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 5", 
                "description": "oral solution BI 639667, dose 5", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 5", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 7", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 1", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 2", 
                "description": "oral solution BI 639667, dose 2", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 4", 
                "description": "oral solution BI 639667, dose 4", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 6", 
                "description": "oral solution BI 639667, dose 6", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 4", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose 6", 
                "description": "placebo solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 3", 
                "description": "oral solution BI 639667, dose 3", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 639667 dose 7", 
                "description": "oral solution BI 639667, dose 7", 
                "intervention_name": "BI 639667", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 7, 2014", 
        "number_of_arms": "14", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with drug-related adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 19 days postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 120 hours postdose"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 120 hours postdose"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}